Actively Recruiting
Investigating Ubamatamab With and Without Marlotamig in Adults With Advanced or Metastatic Non-Small Cell Lung Cancer
Led by Regeneron Pharmaceuticals · Updated on 2026-10-22
300
Participants Needed
18
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating two study drugs, ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer NSCLC. The study also examines sarilumab to evaluate its potential to manage immune-related side effects caused by ubamatamab. The trial is a phase 2 study focused on treatment-experienced adult participants with advanced or metastatic NSCLC. Participants will receive ubamatamab alone or in combination with marlotamig according to the study protocol. Sarilumab is also studied to address immune-related side effects from ubamatamab. The study uses a randomized, parallel design with multiple experimental arms to compare the effects and interactions of these drugs. Treatment dosing and schedules will follow the protocol, with monitoring of drug levels and antibody formation against the drugs. During the study, participants will undergo regular assessments including scans such as CT or MRI to measure tumor lesions following RECIST v1.1 criteria. Researchers will track side effects, immune reactions, and the presence of antibodies against ubamatamab and marlotamig. The primary outcome measures include tumor response over up to 5 years, with secondary evaluations of safety and drug concentration. Participation duration may extend up to 5 years to assess long-term outcomes and treatment effects.
CONDITIONS
Brief Title
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here